Today on the Daily Dive, we sit down with Jack Yu, managing director of Mernova Medicinal, Creso Pharma’s (ASX: CPH) Canadian licensed producer subsidiary. Jack joins us to discuss his experience within the regulatory regime in Canadian cannabis, growing at scale, challenges frequently overlooked by investors, and the benefits of selling into the European markets.
Creso Pharma is an ASX-listed issuer with operations focused on the use of cannabis and hemp across Canada, Europe, Latin America and Australia. In Canada, the company operates its licensed producer, Mernova Medicinal, in Nova Scotia, which focuses on high quality cannabis production. It’s European operations meanwhile are based in Switzerland, where it focuses on its Animal Health, Nutraceutical, and Cosmetics divisions.
Catch the full interview below.
FULL DISCLOSURE: Creso Pharma is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Creso Pharma on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
